Q4 EPS Estimates for Alpha Cognition Increased by Analyst

Key Points

• HC Wainwright raised its Q4 2027 EPS forecast for Alpha Cognition to $0.01 from a prior estimate of a $0.01 loss, while maintaining a Buy rating and $20 price target.
• Alpha Cognition reported a quarterly loss of $0.40 per share, narrowly missing estimates, but revenue of $6.0 million exceeded the $4.38 million consensus forecast. The company remains significantly unprofitable, with a negative net margin of 153.61%.
• Analyst sentiment remains positive: all four covering analysts rate the stock Buy, with a consensus price target of $17.25. Shares opened at $8.84, compared with a 12-month range of $4.50 to $10.00.

Alpha Cognition Inc. (NASDAQ:ACOG - Free Report) - Research analysts at HC Wainwright boosted their Q4 2027 earnings per share estimates for Alpha Cognition in a research report issued on Monday, August 17th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn $0.01 per share for the quarter, up from their prior estimate of ($0.01). HC Wainwright currently has a "Buy" rating and a $20.00 target price on the stock. The consensus estimate for Alpha Cognition's current full-year earnings is ($1.37) per share.

Alpha Cognition (NASDAQ:ACOG - Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.01). The company had revenue of $6.00 million during the quarter, compared to analyst estimates of $4.38 million. Alpha Cognition had a negative net margin of 153.61% and a negative return on equity of 54.60%.

Several other equities analysts have also recently issued reports on the company. Wall Street Zen upgraded Alpha Cognition from a "sell" rating to a "hold" rating in a research note on Saturday. Raymond James Financial began coverage on shares of Alpha Cognition in a research note on Friday, July 10th. They set an "outperform" rating and a $20.00 target price on the stock. Craig Hallum reaffirmed a "buy" rating and issued a $17.00 target price on shares of Alpha Cognition in a report on Friday. Finally, Maxim Group started coverage on shares of Alpha Cognition in a research note on Friday, May 29th. They issued a "buy" rating and a $12.00 price target for the company. Four equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $17.25.

Alpha Cognition Price Performance

ACOG opened at $8.84 on Tuesday. The business has a fifty day moving average price of $7.80 and a 200 day moving average price of $6.55. Alpha Cognition has a 12 month low of $4.50 and a 12 month high of $10.00. The stock has a market capitalization of $192.45 million, a price-to-earnings ratio of -8.04 and a beta of 2.30.

Institutional Investors Weigh In On Alpha Cognition

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Aristides Capital LLC lifted its position in Alpha Cognition by 1.4% in the first quarter. Aristides Capital LLC now owns 218,510 shares of the company's stock valued at $1,200,000 after acquiring an additional 3,052 shares during the last quarter. Villere ST Denis J & Co. LLC lifted its holdings in shares of Alpha Cognition by 13.2% in the 4th quarter. Villere ST Denis J & Co. LLC now owns 73,875 shares of the company's stock valued at $480,000 after purchasing an additional 8,617 shares during the last quarter. Geode Capital Management LLC purchased a new stake in shares of Alpha Cognition in the 2nd quarter valued at about $112,000. Massar Capital Management LP acquired a new stake in shares of Alpha Cognition in the 2nd quarter valued at about $116,000. Finally, Two Sigma Investments LP acquired a new stake in Alpha Cognition during the 3rd quarter worth $148,000.

Alpha Cognition Company Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source